Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2016. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share acquisition transactions:
- Share Price: 1,380.50 pence per Ordinary Share.
- ADS Price: $40.28 per American Depositary Share (ADS).
- Transaction Type: Re-investment of dividends paid on January 14, 2016, under the GSK 2009 Deferred Annual Bonus Plan.
Material Changes
The filing details changes in the notional interests of specific Directors and PDMRs. No material changes to the company's overall financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is strictly a regulatory disclosure of insider share acquisitions.
Key Facts for Investor Verification
- Transaction Date: Allocations were advised on January 28, 2016, and the report was signed on February 1, 2016.
- Participants: Includes Sir Andrew Witty, Dr. P J T Vallance, Dr. M M Slaoui, and other named PDMRs.
- Acquisition Method: Shares and ADSs were acquired through both personal contribution and matching elements (GSK contribution) of the bonus plan.
- Scope: This document does not contain quarterly or annual financial performance data.